Section 3: Introducing GLP-1 Medications: A New Tool for Metabolic Health In the quest for effective strategies to manage weight and related metabolic conditions, a class of medications known as GLP-1 receptor agonists has emerged as a significant advancement
If a reaction is spreading, warm to the touch, or accompanied by fever, seek medical evaluation promptly
Food and Drug Administration (FDA)-approved glucagon-like peptide-1 receptor agonists (GLP-1) anti-obesity medications, such as Zepbound and Wegovy , are flying off pharmacy shelves
each 10% reduction in homocysteine is associated with 1.45-2.55 reduction in pulse pressure mmHg in patients undergoing hemodialysis (14)(27)(31) Increased urinary excretion of homocysteine in its sulfonated form (36) Omega-3 fatty acids 200-6,000 mg (~98-2,000 mg EPA/490-1,000 mg DHA) per day, for 1-12 months in patients with hyperhomocysteinemia or elevated homocysteine within normal ranges (8)(11)(13)(17)(18)(19)(25)(30)(42)(43) Reduced homocysteine by 1.18-1.58 mol/L on average using wide dose ranges, as shown in meta-analyses (8)(18) Reduced homocysteine by ~2.5-4.0 mol/L in patients with type II diabetes, patients on hemodialysis, or healthy adults using mid-range doses of 2,000-3,600 mg per day for 1-3 months and up to one year (11)(17)(25)(30)(42)(43) Reduced homocysteine by ~1.6 mol/L over 12 months in patients younger than 65 years, previously suffering from myocardial infarction (13) Adjunct therapy with folic acid, vitamin B6, and vitamin B12 improved efficacy (8)(17) Adjunct aerobic exercise and cognitive stimulation may be required for benefit in some populations, including older adults with mild cognitive impairment (19)
These drugs also lower postprandial TGs and apoB48 in humans (5, 14, 15) and in mice through mechanisms requiring the GLP-1R (9)
